You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

logo

Product menu

hero banner hero banner
lungs

Why Ventolin? Do Short-acting beta-agonists (SABAs) relievers still have an important role to play in asthma management?

Ventolin helps treat acute exacerbations of asthma (AEA) with an onset of action within 5 minutes1

  • When used appropriately SABA does not contribute to excess rates of mortality3.
  • Monitoring SABA use can be a valuable tool in assessing asthma control4.
  • Trust Ventolin to deliver quality and efficacy1.

If care is optimal, A patient should only be using their reliever rarely, Instead, they should be relying on their maintenance treatment to maintain asthma control. An ICS-containing fixed-dose daily maintenance regimen can help achieve this2.

LEARN ABOUT THE IMPACT OF ASTHMA

Asthma may impact patients’ everyday lives more than they realise5,6

six in ten

57.1% patients consider their asthma to be 'well' or 'completely controlled' despite frequently experiencing symptoms5

ten percent

Of patients say their asthma is not controlled or poorly controlled6

fifty percent

Report frequent symptoms suggesting that they do not have well controlled asthma6

This figure has been independently created by GSK from the original data. The same results were first published in Chapman KR, et al. Resp Med 2021;186:106524.
*A multinational, cross-sectional online survey of asthma patients (n=1216) and physicians (n=803) in Australia, Canada, China and the Philippines.5
†A multinational, cross-sectional online survey of asthma patients (n=1650) and physicians (n=1080) in Argentina, Brazil, France, Italy and Mexico.6

SABA Safety - Meta-analysis of RCTs from the last 25 years:

In a recent SABA safety meta-analysis, it was found that all-cause mortality was rare when SABA was used appropriately as prescribed for symptom relief3. 

Recently a meta-analysis of data was conducted from 24 trials over the past 25 years from ~5000 patients with SABA reliever therapy3.

asthama-pump

When used appropriately within prescribed limits for symptom relief, SABA does not contribute to excess rates of mortality, even in patients with mild to moderate asthma3

safety

Severe Adverse Events (SAE) risk was comparable between SABA and ICS treatments (incidence: 0–5% for both treatments)3

ban

Till date, there has been no Randomized Clinical Trial (RCT) linking asthma mortality associated with SABA use3

Learn more about why Ventolin is "Your Trusted Reliever" Beyond generations

Visit our Trusted Reliever Page to learn more about the legacy of Ventolin over the last 50 years.

trusted_reliever

Important product Information

Prescribing information

Optional secondary information

OPEN

Ventolin safety information1

  • Contraindications:

    Hypersensitivity to the active substance or any of the excipients.

    Non-i.v. formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.

  • Undesirable effects

    Common: Tremor, headache and Tachycardia

Abbreviations

AEA: Acute exacerbation of asthma, SABA: Short-Acting Beta Agonists, ICS: Inhaled Corticosteroids,

References

  1. Ventolin Prescribing Information
  2. Domingo C;Adv Ther ;2023;40;1301-1316
  3. Sriprasart T;Adv Ther;2022;1-26
  4. Amirav I;Adv Ther;2023;40;2927-2943
  5. Chapman KR, et al. Resp Med 2021;186:106524
  6. Chapman KR, et al. Resp Med 2022;201:106948
  7. Sriprasart T;Adv Ther;2022;1-26
  8. GSK. Salbutamol (inhaled formulations) Global Datasheet: v26, April 2019; 2. GINA 2022. Available from: https://ginasthma.org/gina-reports/. (Accessed March 2023).

GSK does not recommend, endorse, or accept liability for the site.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-SLB-WCNT-240003 | Date of Preparation February 2025